Juana Hernandez

Most-cited papers

1. Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

   A. Handra-Luca, Juana Hernandez, G. Mountzios, E. Taranchon +3 more

   2007Clinical Cancer Research136 citations

   Semantic Scholar

   Save

2. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.

   B. Coudert, J. Pierga, M. Mouret-Reynier, K. Kerrou +16 more

   2014The Lancet Oncology114 citations

   Semantic Scholar

   Save

3. DNA Damage Repair and Telomere Length in Normal Breast, Preneoplastic Lesions, and Invasive Cancer

   C. Raynaud, Juana Hernandez, F. Llorca, P. Nuciforo +6 more

   2010American Journal of Clinical Oncology65 citations

   Semantic Scholar

   Save

4. Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

   J. Pierga, T. Petit, C. Lévy, J. Ferrero +10 more

   2014Clinical Cancer Research61 citations Open access

   Semantic Scholar

   Save

5. A retrospective study on the management of patients with rituximab refractory follicular lymphoma

   P. Solal-Céligny, P. Leconte, A. Bardet, Juana Hernandez +1 more

   2018British Journal of Haematology7 citations

   Semantic Scholar

   Save

6. AVATAXHER: An open-label, randomized, multicenter study investigating the addition of bevacizumab (B) to neoadjuvant trastuzumab (T) plus docetaxel (D) in patients with early stage HER2-positive breast cancer (HER2+ BC) stratified according to PET change after one therapy cycle.

   B. Coudert, J. Pierga, M. Mouret-Reynier, K. Kerrou +16 more

   20144 citations

   Semantic Scholar

   Save

7. [Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France].

   J. Pierga, R. Delva, X. Pivot, M. Espié +8 more

   2014Bulletin du Cancer3 citations

   Semantic Scholar

   Save

8. 333PCIRCULATING TUMOR CELL COUNT AT BASELINE IS AN INDEPENDENT PROGNOSTIC FACTOR FROM PATHOLOGICAL COMPLETE RESPONSE AMONG PATIENTS TREATED FOR PRIMARY INFLAMMATORY HER2-POSITIVE BREAST CANCER: SURVIVAL RESULTS OF THE BEVERLY-2 STUDY.

   J. Pierga, T. Petit, C. Lévy, J. Ferrero +11 more

   2014Annals of Oncology1 citations Open access

   Semantic Scholar

   Save

9. Abstract P6-12-06: Three-year follow up results of a phase II study of neoadjuvant bevacizumab, chemotherapy, and trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY2 study

   P. Viens, T. Petit, C. Lévy, J. Ferrero +11 more

   20130 citations

   Semantic Scholar

   Save

10. Desensitization and Induction Immunosuppressive Therapy in Highly HLA-Sensitized Patients Receiving Cadaveric Renal Allograft)

    Juana Hernandez, J. M. Delgado, D. Marrero

    20110 citations Open access

    Semantic Scholar

    Save

11. Quality of life (QOL) after long-term follow-up in patients with early breast cancer (EBC)

    A. Lot, Juana Hernandez, S. Delaloge, M. Spielmann +5 more

    20080 citations

    Semantic Scholar

    Save

12. hTert, MMP1, Her2 expressions by preneoplastic lesions and breast cancer risk.

    Juana Hernandez, M.-C. Mathieu, E. Taranchon, M. Spielmann +3 more

    2006Journal of Clinical Oncology0 citations

    Semantic Scholar

    Save